POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Resources for you and your patients.
Bristol Myers Squibb is dedicated to helping your patients start and continue POMALYST® (pomalidomide) treatment until disease progression or unacceptable toxicity.
Resources and tools
for HCPs.

Help patients with the information they need.

POMALYST is only available through a restricted distribution program called the POMALYST REMS® program.


POMALYST is only available through a select network of specialty pharmacies.

Reference: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp.